Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 791-793

  Perkhofer, Susanne ^a   Lugger, Helene ^a   Dierich, Manfred P ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONIDIUM; CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS HYPHAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 33846585413     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01024-06     Document Type: Article

References (24)

1. Bauters, T., F. Buyle, R. Peleman, and H. Robays. 2005. Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist. Pharm. World Sci. 27:31-34.
2. Bernard, M., and J. P. Latgè. 2001. Aspergillus fumigatus cell wall: composition and biosynthesis. Med. Mycol. 39(Suppl. 1):9-17.
3. Cacciapuoti, A., M. Gurnani, J. Halpern, C. Morris, R. Patel, and D. Loebenberg. 2005. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob. Agents Chemother. 49:638-642.
4. Cacciapuoti, A. D., D. Loebenberg, E. Corcoran, F. Menzel, E. L. Moss, C. Norris, M. Michalski, K. Raynor, J. Halpern, C. Mendrick, B. Arnold, B. Antonacci, R. Parmegiani, T. Yarosh-Tomaine, G. H. Miller, and R. S. Hare. 2000. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent against Aspergillus and Candida. Antimicrob. Agents Chemother. 44:2017-2022.
5. Cuenca-Estrella, M., A. Gomez-Lopez, G. Garcia-Effron, L. Alcazar-Fuoli, E. Mellado, M. Buitrago, and J. L. Rodriguez-Tudela. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:1232-1235.
6. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
7. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
8. Garber, G. 2001. An overview of fungal infections. Drugs 61(Suppl. 1):1-12.
9. Groll, A., and J. T. Walsh. 2005. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti-Infect. Ther. 4:467-487.
10. Hogan, L. H., B. S. Klein, and S. M. Levitz. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 4:469-488.
11. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
12. Lass-Flörl, C., M. Nagl, C. Speth, H. Ulmer, M. P. Dierich, and R. Würzner. 2001. Studies of the in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob. Agents Chemother. 45:124-128.
13. Levitz, S. M., and R. D. Diamond. 1985. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J. Infect. Dis. 5:938-945.
14. Najvar, L. K., A. Cacciapuoti, S. Hernandez, J. Halpern, R. Bocanegra, M. Gurnani, F. Menzel, D. Loebenberg, and J. R. Graybill. 2004. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob. Agents Chemother. 48:758-764.
15. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
16. Polak, A. 1999. The past, present, and future of antimycotic combination therapy. Mycoses 42:355-370.
17. Raad, I. I., J. R. Graybill, A. B. Bustamante, O. A. Cornely, V. Gaona-Flores, C. Afif, D. R. Graham, R. N. Greenberg, S. Hadley, A. Langston, R. Negroni, J. R. Perfect, P. Pitisuttithum, A. Restrepo, G. Schiller, L. Pedicone, and A. J. Ullmann. 2006. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42:1726-1734.
18. Richardson, M. D. 1998. Antifungal therapy in bone marrow failure. Br. J. Haematol. 100:619-628.
19. Steinbach, W., D. A. Stevens, and D. W. Denning. 2003. Combination and sequential therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37:S188-S224.
20. Sugar, A. M., and X. P. Liu. 1998. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J. Infect. Dis. 77:1660-1663.
21. Sugar, A. M. 1991. Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination. Antimicrob. Agents Chemother. 35:1669-1671.
22. Torres, H. A., R. Hachem, R. F. Chemaly, D. P. Kontoyiannis, and I. Raad. 2005. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 12:775-785.
23. Walsh, T. J., H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, and B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 347:1391-1402.
24. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinbardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, E. Anaissie, and J. Lee. 2002. Voriconazole compared with liposomal amphotericin B for empirical anti-fungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.